Zevra Therapeutics Inc (NASDAQ: ZVRA) on Friday, soared 4.87% from the previous trading day, before settling in for the closing price of $8.83. Within the past 52 weeks, ZVRA’s price has moved between $4.20 and $9.76.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.96%. The company achieved an average annual earnings per share of 90.90%. With a float of $54.08 million, this company’s outstanding shares have now reached $54.68 million.
Let’s determine the extent of company efficiency that accounts for 59 employees. In terms of profitability, gross margin is 78.84%, operating margin of -177.09%, and the pretax margin is -185.68%.
Zevra Therapeutics Inc (ZVRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zevra Therapeutics Inc is 1.10%, while institutional ownership is 65.35%. The most recent insider transaction that took place on Mar 28 ’25, was worth 2,352. In this transaction Director of this company bought 300 shares at a rate of $7.84, taking the stock ownership to the 1,800 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Director bought 10,000 for $7.96, making the entire transaction worth $79,624. This insider now owns 40,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 90.90% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
Zevra Therapeutics Inc (ZVRA) is currently performing well based on its current performance indicators. A quick ratio of 2.93 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.89, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach 0.67 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Looking closely at Zevra Therapeutics Inc (NASDAQ: ZVRA), its last 5-days average volume was 0.68 million, which is a jump from its year-to-date volume of 0.49 million. As of the previous 9 days, the stock’s Stochastic %D was 81.92%. Additionally, its Average True Range was 0.37.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 96.24%, which indicates a significant increase from 89.74% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.73% in the past 14 days, which was lower than the 47.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.79, while its 200-day Moving Average is $8.03. However, in the short run, Zevra Therapeutics Inc’s stock first resistance to watch stands at $9.45. Second resistance stands at $9.64. The third major resistance level sits at $9.90. If the price goes on to break the first support level at $9.00, it is likely to go to the next support level at $8.74. Should the price break the second support level, the third support level stands at $8.55.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
Market capitalization of the company is 506.33 million based on 54,680K outstanding shares. Right now, sales total 23,610 K and income totals -105,510 K. The company made 20,400 K in profit during its latest quarter, and -3,100 K in sales during its previous quarter.
